Resmed (RMD) reported Thursday Q4 adjusted earnings of $2.95 per diluted share, up from $2.55 a year earlier.
Analysts polled by FactSet expected $2.89.
Revenue for the quarter ended June 30 was $1.46 billion, up from $1.35 billion a year ago.
Analysts surveyed by FactSet expected $1.46 billion.